Safety and effectiveness of sucroferric oxyhydroxide in Spanish dialysis patients: A sub-analysis of the VERIFIE study

No Thumbnail Available
Auxiliadora Bajo, Maria
Rios Moreno, Francisco
Dolores Arenas, Maria
Deuesa Such, Ramon Jesus
Molina Higueras, Maria Jose
Delgado, Margarita
Molina, Pablo
Garcia Fernandez, Nuria
Martin Malo, Alejandro
Peiro-Jordan, Roser
Journal Title
Journal ISSN
Volume Title
Soc espanola nefrologia dr rafael matesanz
Research Projects
Organizational Units
Journal Issue
Background and aims: In this study, we show the results of the subset of Spanish patients of the VERIFIE study, the first post-marketing study assessing the long-term safety and effectiveness of sucroferric oxyhydroxide (SFOH) in patients with hyperphosphatemia undergoing dialysis during clinical practice.Patients and methods: Patients undergoing hemodialysis and peritoneal dialysis with indication of SFOH treatment were included. Follow-up duration was 12-36 months after SFOH initiation. Primary safety variables were the incidence of adverse drug reactions, medical events of special interest, and variations in iron-related parameters. SFOH effectiveness was evaluated by the change in serum phosphorus levels.Results: A total of 286 patients were recruited and data from 282 were analyzed. Among those 282 patients, 161 (57.1%) withdrew the study prematurely and 52.5% received concomitant treatment with other phosphate binders. Adverse drug reactions were observed in 35.1% of patients, the most common of which were gastrointestinal disorders (77.1%) and mild/moderate in severity (83.7%). Medical events of special interest were reported in 14.2% of patients, and 93.7% were mild/moderate. An increase in ferritin (386.66 ng/mL vs 447.55 ng/mL; P = .0013) and transferrin saturation (28.07% vs 30.34%; P=.043) was observed from baseline to the last visit. Serum phosphorus levels progressively decreased from 5.69 mg/dL at baseline to 4.84 mg/dL at the last visit (P
MeSH Terms
DeCS Terms
CIE Terms
Dialysis, Sucroferric oxyhydroxide, Phosphate binder, Safety, Clinical practice, Chronic kidney-disease, Phosphate binder pa21, Hemodialysis-patients, Hyperphosphatemia, Efficacy, Bone